Compare Incyte Corporation (INCY) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Consumer Staples Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Incyte Corporation is the larger of the two by market cap, and Consumer Staples Select Sector SPDR Fund is more actively traded (14,599,953 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| INCY | XLP | |
|---|---|---|
Market Cap | $22.85B | $13.50B |
Volume | 1,927,029 | 14,599,953 |
Sector | Health | — |
52-Week High | $129.93 | $90.00 |
52-Week Low | $83.80 | $75.61 |
Typical Hold Time | 33 Days | 72 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
XLP trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong relative performance against discretionary peers, gaining 6.6% year-to-date while XLY declined over 7%. Analyst consensus is unanimously bullish with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peer funds.
The outlook remains positive given XLP's defensive positioning in consumer staples, low 0.08% expense ratio, and strong technical momentum. However, risks include sensitivity to interest rate movements and potential consumer spending slowdown. The ETF's proximity to resistance at $84 suggests near-term consolidation may precede further upside if bullish momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
